Molecular hybridization with radioactively labeled DNA complementary to the RNA of the Rauscher leukemia virus was used to probe for homologous RNA in human lymphomas. 22 of 32 specimens contained RNA possessing homology to the RNA of the mouse leukemia virus, but not to that of the unrelated viruses causing mammary tumors in mice or myeloblastosis in chickens. Normal adult and fetal tissues failed to show significant levels of the leukemia-specific RNA. It appears that human lymphomas contain RNA sequences homologous to those found in a viral agent known to cause leukemia and lymphomas in an experimental animal. The fact that human leukemias and sarcomas also contain this type of RNA further emphasizes a remarkable similarity between the corresponding neoplasias of murine and human origin.
We have used molecular hybridization to detect virusspecific RNA in tumors (l), and have found that corresponding neoplasias of murine and human origin exhibit remarkable similarities. Thus, human breast carcinomas contained (2) RNA possessing sequence homology to that of mouse mammary tumor virus (MMTV). This type of RNA was unique to the malignant adeno-and medullary-carcinomas, being undetectable in normal breast tissue and in such benign pathologies as fibrocystic disease and fibroadenoma. I n keeping with the known unrelatedness of the leukemogenic and mammary tumor viruses, we found that breast cancer RNA did not hydridize to DNA complementary to the RNA of Rauscher leukemia virus (RLV). Finally, and most compelling, was the demonstration that human leukemic cells (3) and human sarcomas (4) both contain RNA showing homology to that of Rauscher leukemia virus, and not to that of mouse mammary tumor virus. It was of obvious interest to pursue this intriguing concordance between the neoplasias of mice and men.
From the viewpoint of etiology and cellular pathology, lymphomas in mice are linked to the leukemias and sarcomas. I n addition, it may be noted that some human lymphomas are accompanied by the clinical appearance of a peripheral leukemia. In any event, if human neoplasias parallel those observed in mice it might be expected that human lymphomas would, like the leukemias and sarcomas, contain RNA uniquely homologous to that of a mouse leukemia agent.
We report here a confirmation of this expectation. Human lymphomas, including Hodgkins' disease, lymphosarcomas, and reticulum cell sarcomas contain RNA exhibiting homology to the RNA of Rauscher leukemia virus, but not to the unrelated RNAs of either mouse mammary tumor virus or of avian myeloblastosis virus (AhIV) .
Abbreviations: RLV, Rauscher (murine) leukemia virus; pRNA, cytoplasmic (polysomal) RNA; AMV, avian myeloblastosis virus; MMTV, mouse mammary tumor virus.
METHODS AND MATERIALS
Preparation of Nucleic Acids. The preparation of labeled DNA is exemplified in the case of RLV-13H]DNA. A 1-ml reaction mixture, containing 100 pg of viral protein prepared from virus purified from plasma (5), 50 mM Tris.HC1 (pH 8.3), 40 mM KC1, 6 mM MgC12, 2.5 mM dithiothreitol, 0.00125% Nonidet (NP-40), 100 mM (each) of dGTP, dATP, and dCTP, and 5 X lo4 pmol of [3H]TTP (8000 cpm/pmol), was incubated a t 37" for 180 min. After the addition of sodium dodecyl sulphate to 0.5%, the nucleic acid was extracted with an equal volume of phenol-cresol, and the [3H]DNA product was purified by passage through a Sephadex G-50 column, followed by incubation in 0.5 M NaOH a t 43" for 24 hr to remove viral RNA. MMTV-[3H]DNA and AMV-[aH]DNA were prepared in a similar manner.
For the preparation of cytoplasmic RNA (designated as pRNA), the tumors were disrupted with a Silverson homogenizer a t 4" in 2 volumes of 5% sucrose in T N M buffer (0.01 M Tris.HC1, pH 7.4-0.15 M NaC1-2 mM MgC12). The suspension was centrifuged at 20,000 X g for 15 min a t 0" to remove nuclei and cell debris. The supernatant fluid was layered on 20 ml of 25% sucrose containing 200 pg of polyvinyl sulfate per ml and centrifuged a t 4" for 180 min a t 180,000 X g in a 60-Ti rotor (Spinco). The pellet was resuspended in T N M buffer containing 0.5% sodium dodecyl sulfate and the RNA was extracted twice with an equal volume of cresol-phenyl (pH 8.0). The aqueous phase was adjusted to 0.4 M NaC1, and the nucleic acid was precipitated with two volumes of ethanol. The resulting pRNA precipitate was dissolved in minimum volume of 50% formamide-3 mM EDTA.
Annealing Reactions Between p R N A and [3H]
DNA. Immediately before use, [3H]DNA was denatured by incubation for 10 min a t 80" in 75% formamide, followed by quick chilling a t 0". The annealing mixture usually contained 350 pg of pRNA and 2000 cpm of [3H]DNA in 60 pl of 0.4 M NaC1, adjusted to 50% formamide and pH 7.4. Annealing was for 18 hr a t 37", after which 10 ml of Cs2S04 a t 50% saturation (density: 1.52 g/ml) was added; the resulting solution was centrifuged a t 44,000 rpm for 60 hr a t 15" in a 50-Ti rotor (Spinco). Fractions (0.4 nil) were collected through a needle inserted in the bottom of the tube and assayed (3) for acid-precipitable (10% trichloroacetic acid) radioactivity.
Pitfalls to be Guarded Against. The experiments described here and in our previous studies on breast cancer (2), the leukemias (3) and the sarcomas (4) were designed to detect in the neighborhood of 0.1 ng or less of complementary RNA in the pRNA preparations being tested. The sensitivity of the method is therefore being pushed towards its limit. Under the To insure the interpretability of the results, it is imperative that every purified [3H]DNA preparation used be monitored for adequacy by being subjected to the following tests: (a) It must be shown to band cleanly in the appropriate DNA region of the density gradient to insure that it is free of contaminating viral RNA; (b) It must be extensively hybridizable . to the homologous viral RNA used as the template in the original synthesis. This can exceed 90% in the presence of excess viral RNA if actinomycin D, a t a concentration of 100 pg/ml, is included to prevent DNA-directed DNA synthesis, a possibility particularly prevalent in crude enzyme preparations; and ( 6 ) The [3H]DNA product should not hybridize to unrelated viral RNA or to RNA from normal tissues. We customarily use the RNAs from AMV, RLV, and MMTV as test objects for cross-hybridizability checks. A suitable synthetic DNA complementary to any one of them will not hybridize to either of the other two or to pRNA from normal tissue.
It is not a trivial matter to obtain nucleic acid preparations that will satisfy all of these criteria. It is, unfortunately, not uncommon to obtain DNA preparations that fail the third requisite of specific hybridizability to its homologous RNA.
This failure may stem from slight contamination with cellular DNA in the synthesis mixture, in which case the product will contain labeled DNA that will hybridize to both normal and tumor RNA. Another source of confusion is the possible complementary copying of long stretches of adenylate residues that are present in oncogenic RNAs (6, 7) and in normal cellular messages (8, 9).
[3H]DNA with the resulting blocks of T residues will hybridize to any RNA containing corresponding blocks of A. This difficulty is greatly magnified by the use of oligo(dT) as a primer to enhance synthesis, a procedure that should be avoided when specific probes are made. One
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Viral-Related RNA in Hodgkins' Disease 1729 can readily test for the occurrence of this type of pairing by esamining the effect of prehybridizing with unlabeled oligo(rU).
Every [3H]DNA used as a probe in the present and previous ( 1 4 ) studies successfully passed the three tests outlined above. We cannot overemphasize the need for exercise of the precautions noted in investigations along these lines.
Unless the materials used satisfy the criteria stipulated, the resulting esperiments are likely to generate more confusion than information.
RESULTS
We first illustrate (Fig. 1A-C) representative outcomes of hybridizations between RLV [ 3H]DNA and the pRNA prepared from three types of human lymphomas. Between 2 and 6% of the [3H]DNA is shifted to the RNA region of the Csy SO1 gradient. The position of the complex implies that the RNA is much larger than the DNA and, thus, determines the density of the hybrid structure. The amounts of RLV[3H]-DNA involved in the complexes are comparable to those we haye seen in similar experiments with pRNA from human sarcomas (4) and human leukemic white blood cells (3).
Fig . 1D compares the responses of pRNA preparations from spleens of normal humans and those with Hodgkins' disease a t various concentrations of pRNA. No detectable reaction is obtained with normal spleen pRNA, even a t the highest concentration tested, which was in excess of 7 mg/ml. Within the same range, the pRNA derived from the spleen of the patient with Hodgkins' disease complexed with somewhat more than 2y0 of the RLVj3H]DNA, with no evidence of saturation at 6.7 mg of pRNA per ml.
Since it is unwieldy to detail the Cs2SO4 gradient profile of every sample tested, we have adopted a more convenient recording of our data. After correction for background, the tritium counts in the density region of RNA (1.62-1.69 g/ml) were taken as a measure of the amount of [3H]DNA complexed to RNA. To attain the statistical accuracy desired, 10-min counts (cplOm) were taken on each sample. The convention was adopted that hybridization was negative if the sum of the cplOm in the RNA density region was less than three standard deviations above the mean background in the same region. Table 1 lists the lymphoma samples tested for RNA related to the DNA of RLV. The results are recorded in counts per 10 min (corrected for background) in the RNA density region, and as multiples of the mean background standard deviation. Included are 24 Hodgkins' lymphomas, three reticulum cell sarcomas, and five Iymphosarcomas. Of the 32 lymphomas, 22 (or 69Oj,) gave clear indications of containing RNA homologous to the RNA of RLV. This result is in sharp contrast to the results obtained with pRNA from normal adult and fetal tissues ( Table 2) . None of the 48 normal preparations tested gave a reaction that could be accepted unambiguously as positive. Fig. 2 provides a convenient pictorial summary as multiples of the mean background standard deviation.
The fact that 69% of the pRNAs derived from lymphomas yielded positive hybridizations with RLV-DNA, whereas none of the 48 control tissues (Table 2, Fig. ID 
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Reticulum cell sarcomas and the reactions were subjected to CszSOa equilibrium centrifugation. The data are expressed as cplOm (corrected for background) that bands in the RNA region of the gradient, and as multiples of the standard deviation ( S ) , as described in Fig. 2 and Table l.
* See Table 1. DNA or AMV-DNA. Fig. 3A and B show that these expectations are realized. Two Hodgkins' lymphoma pRNAs, positive for reactions with RLV-DNA, show no significant reactions with either AMV-DNA or MMTV-DNA.
DISCUSSION
The absence of positive reactions with the pRNA preparations from certain of the lymphomas may raise questions of universality in the minds of some. However, it must be recognized that a negative outcome cannot be accepted as evidence for the nonexistence of the relevant RNA, whether the tissue being tested is neoplastic or normal. The sensitivity of the method is, at present, principally limited by the amount of RNA that can be dissolved in the annealing mixture, a difficulty that will be greatly obviated by the development of a suitable enrichment procedure for the pertinent RNA fraction. As in the instances of the leukemias (3) and sarcomas (4), we can at best conclude that the probability of finding RNA homologous to RLV-RNA is much greater in human lymphoma cells than in normal tissues. Indeed, if the provirus (10) or oncogene (11) hypotheses are valid, some part of this oncogenic information could be expressed and detected with the aid of more sensitive tests in certain normal tissues that have been reported (12) to exhibit group-specific antigens of the mammalian leukemogenic viruses. (0), and striated muscle (G); and fetal tissues: liver (A), lung (V), limbs (0), and placenta (0). The reactions were centifuged in Cs2SOa equilibrium density gradients. The amount of [3H]DNA, expressed as cpl0m corrected for background, banding in the density region of RNA (between densities 1.62 and 1.69), was determined for each reaction. An operational mean and standard deviation ( 8 ) were then determined for each counter by the total cplOm of three tubes (e.g., 2,3,4) of each of 60 gradients. The number of [3H]DNA cpl0m corrected for background banding in the RNA region of the gradient was then divided by the appropriate operational standard deviation. Any reaction with cpl0m in the RNA region less than 3S is considered negative, thus providing 9(3.9cj, confidence that those reactions retained as positive (greater than 3s) are significant. (ii) How much homology does it in fact have to the RLV-RNA? and (iii) Is the viral-related RNA associated with a reverse transcriptase (RNA-instructed DNA polymerase) and is it located in structures characteristic of incomplete or complete virus particles? The requisite techniques have been developed to answer these questions with respect to the human rieoplasias we have studied, and the experiments are underway.
Discovery of RNA homologous to that of the murine leukemia virus in human lymphomas immediately raises the issue of Burkitt's disease, a malignant lymphoma found in children living in a geographical belt extending across Central Africa. There exists serological (13) and nucleic acid hybridiaation (14) evidence linking this disease to the Epstein-Barr virus (EBV), a herpes-like virus that contains DNA detected in (15), and isolated (16), from Burkitt's lymphoma cells grown in culture. Since a causal relation between EpsteinBarr virus and Burkitt's tumor has not been established, it is pertinent to inquire whether this lymphoma, like the others examined here, also contains RLV-related RNA.
In many ways the most noteworthy features of our studies of human neoplasias emerge when they are compared with one another, and to this end a composite of the results we have thus far accumulated is presented in Table 3 . Breast cancer The results of molecular hybridization between DNA complementary to the various viral RNAs arid pRNA preparations from the indicated neoplastic tissues. A plus sign indicates that hybridizations were positive and a minus sign that no hybridization could be detected.
contains RNA homologous only to that of the murine mammary tumor virus. Leukemias, sarcomas, and lymphomas all contain RNA homologous to that of the Rauscher leukemia virus and not to MMTV-RNA. Finally, none of the human tumors contains RNA detectably related to the RNA of the avian myeloblastosis virus.
It is clear that with all four human neoplasias examined, the specificity pattern of the RNA they contain is in complete accord with what has been observed in the corresponding viral-induced malignancies in the mouse.
